WO2018208124A3 - 이소트레티노인과 펩타이드의 결합체 - Google Patents

이소트레티노인과 펩타이드의 결합체 Download PDF

Info

Publication number
WO2018208124A3
WO2018208124A3 PCT/KR2018/005447 KR2018005447W WO2018208124A3 WO 2018208124 A3 WO2018208124 A3 WO 2018208124A3 KR 2018005447 W KR2018005447 W KR 2018005447W WO 2018208124 A3 WO2018208124 A3 WO 2018208124A3
Authority
WO
WIPO (PCT)
Prior art keywords
isotretinoin
antibiotic
inflammatory
linked
peptide
Prior art date
Application number
PCT/KR2018/005447
Other languages
English (en)
French (fr)
Other versions
WO2018208124A2 (ko
Inventor
정용지
김은미
Original Assignee
(주)케어젠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA201992544A priority Critical patent/EA201992544A1/ru
Priority to US16/612,125 priority patent/US11351266B2/en
Priority to AU2018264739A priority patent/AU2018264739B2/en
Priority to BR112019023568-0A priority patent/BR112019023568A2/pt
Priority to EP18797674.1A priority patent/EP3613438A4/en
Priority to CN201880031088.XA priority patent/CN110612125B/zh
Priority to CA3063268A priority patent/CA3063268C/en
Priority to JP2019561984A priority patent/JP7016886B2/ja
Application filed by (주)케어젠 filed Critical (주)케어젠
Priority to MX2019013467A priority patent/MX2019013467A/es
Publication of WO2018208124A2 publication Critical patent/WO2018208124A2/ko
Publication of WO2018208124A3 publication Critical patent/WO2018208124A3/ko
Priority to SA519410507A priority patent/SA519410507B1/ar
Priority to PH12019502514A priority patent/PH12019502514A1/en
Priority to US17/736,261 priority patent/US12005123B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 이소트레티노인과 펩타이드가 공유결합으로 연결된 구조를 갖는 화합물 및 이를 포함하는 항균, 항염증 또는 항산화용 약학적 조성물 또는 화장료 조성물에 관한 것이다. 본 발명의 이소트레티노인과 펩타이드가 공유결합으로 연결된 구조를 갖는 화합물은 항균, 항염증, 또는 항산화 작용과 같은 생리활성이 우수할 뿐만 아니라 물에서의 용해도 등의 특성이 뛰어나므로, 의약품 또는 화장품 등의 다양한 분야에 유용하게 사용될 수 있다.
PCT/KR2018/005447 2017-05-11 2018-05-11 이소트레티노인과 펩타이드의 결합체 WO2018208124A2 (ko)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CA3063268A CA3063268C (en) 2017-05-11 2018-05-11 Conjugate of isotretinoin and peptide
AU2018264739A AU2018264739B2 (en) 2017-05-11 2018-05-11 Conjugate of isotretinoin and peptide
BR112019023568-0A BR112019023568A2 (pt) 2017-05-11 2018-05-11 Conjugado de isotretinoína e peptídeo
EP18797674.1A EP3613438A4 (en) 2017-05-11 2018-05-11 CONJUGATE OF ISOTRETINOINE AND PEPTIDE
CN201880031088.XA CN110612125B (zh) 2017-05-11 2018-05-11 异维a酸和肽的偶联物
EA201992544A EA201992544A1 (ru) 2017-05-11 2018-05-11 Конъюгат изотретиноина с пептидом
JP2019561984A JP7016886B2 (ja) 2017-05-11 2018-05-11 イソトレチノインとペプチドの結合体
US16/612,125 US11351266B2 (en) 2017-05-11 2018-05-11 Conjugate of isotretinoin and peptide
MX2019013467A MX2019013467A (es) 2017-05-11 2018-05-11 Conjugado de isotretinoina y peptido.
SA519410507A SA519410507B1 (ar) 2017-05-11 2019-11-07 مترافق من آيزوتريتينوين وببتيد
PH12019502514A PH12019502514A1 (en) 2017-05-11 2019-11-08 Conjugate of isotretinoin and peptide
US17/736,261 US12005123B2 (en) 2017-05-11 2022-05-04 Conjugate of isotretinoin and peptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170058866A KR102093209B1 (ko) 2017-05-11 2017-05-11 이소트레티노인과 펩타이드의 결합체
KR10-2017-0058866 2017-05-11

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/612,125 A-371-Of-International US11351266B2 (en) 2017-05-11 2018-05-11 Conjugate of isotretinoin and peptide
US17/736,261 Division US12005123B2 (en) 2017-05-11 2022-05-04 Conjugate of isotretinoin and peptide

Publications (2)

Publication Number Publication Date
WO2018208124A2 WO2018208124A2 (ko) 2018-11-15
WO2018208124A3 true WO2018208124A3 (ko) 2019-03-28

Family

ID=64105520

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/005447 WO2018208124A2 (ko) 2017-05-11 2018-05-11 이소트레티노인과 펩타이드의 결합체

Country Status (13)

Country Link
US (2) US11351266B2 (ko)
EP (1) EP3613438A4 (ko)
JP (1) JP7016886B2 (ko)
KR (1) KR102093209B1 (ko)
CN (1) CN110612125B (ko)
AU (1) AU2018264739B2 (ko)
BR (1) BR112019023568A2 (ko)
CA (1) CA3063268C (ko)
EA (1) EA201992544A1 (ko)
MX (1) MX2019013467A (ko)
PH (1) PH12019502514A1 (ko)
SA (1) SA519410507B1 (ko)
WO (1) WO2018208124A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240069119A (ko) * 2022-11-11 2024-05-20 (주)더마펌 항균, 항염증 또는 항여드름용 펩타이드 및 이를 포함하는 화장료 조성물
CN118126119A (zh) * 2024-05-10 2024-06-04 荷本世新(北京)生物科技有限公司 维a酸多肽衍生物及其制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060091829A (ko) * 2005-02-15 2006-08-22 (주)한국스티펠 레티노이드를 유효성분으로 하는 백반증 예방 및 치료용 약학적 조성물
KR20070038509A (ko) * 2004-07-09 2007-04-10 디에스엠 아이피 어셋츠 비.브이. 레티노산의 아미노, 아미노산 또는 펩타이드 결합체
KR20070091613A (ko) * 2004-11-08 2007-09-11 그렌마크 파머수티칼스 엘티디. 항여드름 화합물 및 항생제 화합물을 함유하는 국소적 제약조성물
KR101224809B1 (ko) * 2012-04-24 2013-01-21 주식회사 아이피어리스 레티노산 유도체, 이의 제조 방법 및 이를 포함하는 화장품 조성물
KR20160121802A (ko) * 2016-10-13 2016-10-20 (주)케어젠 성장인자 활성을 나타내는 펩타이드 및 그의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4371673A (en) 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
IN190846B (ko) 1999-07-30 2003-08-23 Ranbaxy Lab Ltd
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
WO2003037385A1 (en) 2001-10-30 2003-05-08 Nektar Therapeutics Al, Corporation Water-soluble polymer conjugates of retinoic acid
KR20040040792A (ko) 2002-11-08 2004-05-13 주식회사 엘지생활건강 아미노산 또는 펩타이드가 결합된 레티놀 유도체 및 이를포함하는 피부노화 방지용 화장료 조성물
WO2009036368A2 (en) 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
ES2358829B1 (es) * 2009-10-23 2012-06-25 Lipotec, S.A. Péptidos útiles en el tratamiento y/o cuidado de la piel, mucosas y/o cabello y su uso en composiciones cosméticas o farmacéuticas.
KR20150130614A (ko) * 2014-05-13 2015-11-24 (주)케어젠 성장인자 활성을 나타내는 펩타이드 및 그의 용도

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070038509A (ko) * 2004-07-09 2007-04-10 디에스엠 아이피 어셋츠 비.브이. 레티노산의 아미노, 아미노산 또는 펩타이드 결합체
KR20070091613A (ko) * 2004-11-08 2007-09-11 그렌마크 파머수티칼스 엘티디. 항여드름 화합물 및 항생제 화합물을 함유하는 국소적 제약조성물
KR20060091829A (ko) * 2005-02-15 2006-08-22 (주)한국스티펠 레티노이드를 유효성분으로 하는 백반증 예방 및 치료용 약학적 조성물
KR101224809B1 (ko) * 2012-04-24 2013-01-21 주식회사 아이피어리스 레티노산 유도체, 이의 제조 방법 및 이를 포함하는 화장품 조성물
KR20160121802A (ko) * 2016-10-13 2016-10-20 (주)케어젠 성장인자 활성을 나타내는 펩타이드 및 그의 용도

Also Published As

Publication number Publication date
US20220265840A1 (en) 2022-08-25
PH12019502514A1 (en) 2020-07-20
CA3063268A1 (en) 2018-11-15
US11351266B2 (en) 2022-06-07
AU2018264739B2 (en) 2020-08-27
WO2018208124A2 (ko) 2018-11-15
CN110612125A (zh) 2019-12-24
EP3613438A4 (en) 2020-05-06
SA519410507B1 (ar) 2023-02-19
JP7016886B2 (ja) 2022-02-07
MX2019013467A (es) 2020-02-12
US20200246473A1 (en) 2020-08-06
JP2020519622A (ja) 2020-07-02
AU2018264739A1 (en) 2019-12-12
EA201992544A1 (ru) 2020-03-13
KR20180124411A (ko) 2018-11-21
BR112019023568A2 (pt) 2020-06-02
KR102093209B1 (ko) 2020-03-25
CA3063268C (en) 2022-06-28
CN110612125B (zh) 2023-06-02
EP3613438A2 (en) 2020-02-26
US12005123B2 (en) 2024-06-11

Similar Documents

Publication Publication Date Title
PH12019501824A1 (en) Anti-gprc5d antibody and molecule comprising the antibody
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
BR112018010683A8 (pt) ?composição, método para produzir uma composição, método que compreende administrar por via enteral uma substância e método para produzir um produto?
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
EA201591632A1 (ru) Цитотоксические и антимитотические соединения и способы их применения
BR112015004600A2 (pt) composições de gluconato de clorexidina, sistemas e artigos de resina
WO2020198403A3 (en) Compositions comprising modified circular polyribonucleotides and uses thereof
MX2019007641A (es) Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
EA202091012A1 (ru) Композиции фосфорилированных тау-пептидов и их применения
PH12019502514A1 (en) Conjugate of isotretinoin and peptide
BR112015028411A2 (pt) formulações estáveis de domínios variáveis únicos de imunoglobulina e uso destas
BR112015031329A2 (pt) composições compreendendo ciclodextrina e ácido hialurônico reticulado
BR112013004436A2 (pt) composições e usos de materiais com atividade microbicida alta e toxicidade baixa
MD3359146T2 (ro) Compoziții farmaceutice și utilizări direcționate spre bolile de depozitare lizozomală
EA201590708A1 (ru) Модифицированные производные гиалуроновой кислоты и их применение
CL2020001322A1 (es) Quitosano con carga aniónica.
MX2018009948A (es) Formulaciones de oritavancina.
BRPI0612534B8 (pt) uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto
WO2016195194A3 (ko) 신규한 tlr2 길항제
ZA201905738B (en) Conjugate of salicylic acid and peptide
AU2017251957A1 (en) Hyaluronic acid conjugates and uses thereof
MX2023001232A (es) Medicamentos antiplaquetarios y usos de estos.
CL2020001323A1 (es) Carboxialquilo de quitosano.
EA202191378A1 (ru) Активные сложноэфирные производные тестостерона, их композиции и применения
WO2020021489A3 (en) Discovery of novel first in class nature-inspired compounds targeting the mitochondrial function and pharmaceutical composition thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18797674

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3063268

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019561984

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3063268

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019023568

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2018797674

Country of ref document: EP

Effective date: 20191122

ENP Entry into the national phase

Ref document number: 2018264739

Country of ref document: AU

Date of ref document: 20180511

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112019023568

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20191108

WWE Wipo information: entry into national phase

Ref document number: 522441026

Country of ref document: SA